Akiva Felt is a research analyst with Franklin Equity Group, specializing in the analysis of biotechnology and biopharmaceutical companies. His research is focused across broad therapeutic areas including neurology, hepatology, GI, and rare diseases.

Mr. Felt joined Franklin Templeton in 2018 and was previously a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund.

He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.

Mr. Felt holds a B.S. in Biomedical Engineering from Washington University in St. Louis and a M.A. in Biotechnology from Columbia University.